☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Kite
Kite (Gilead) and Arcellx Report the Expansion of its Collaboration Agreement for CART-DdBCMA in Multiple Myeloma
November 16, 2023
Kite Reports P-II Study (ALYCANTE) Results of Yescarta (axicabtagene ciloleucel) for Relapsed/Refractory Large B-Cell Lymphoma
September 18, 2023
Kite Reports Real-World Analysis Results of Tecartus (brexucabtagene autoleucel) for Relapsed/Refractory Mantle Cell Lymphoma
June 7, 2023
Kite Reports P-III Study (ZUMA-7) Results of Yescarta for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
March 22, 2023
Kite Reports P-I/II Study (ZUMA-3) Results of Tecartus (brexucabtagene autoleucel) for B-Cell Acute Lymphoblastic Leukemia
February 10, 2023
Kite’s Yescarta Receives EC’s Approval as 2L Treatment of Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
October 18, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.